These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


127 related items for PubMed ID: 33423095

  • 1. Delayed imaging with oral contrast improves [68Ga]Ga-DOTANOC PET/CT detection of primary duodenal neuroendocrine tumor (NET).
    Mei R, Allegri V, Calabrò D, Fanti S, Ambrosini V.
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1684-1685. PubMed ID: 33423095
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of Contrast-Enhanced CT + CT Enterography and 68Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors.
    Sharma A, Das CJ, Makharia GK, Arora G, Kumar R.
    Clin Nucl Med; 2020 Nov; 45(11):848-853. PubMed ID: 32657875
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
    Crown A, Rocha FG, Raghu P, Lin B, Funk G, Alseidi A, Hubka M, Rosales J, Lee M, Kennecke H.
    J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
    [Abstract] [Full Text] [Related]

  • 13. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients.
    Berzaczy D, Giraudo C, Haug AR, Raderer M, Senn D, Karanikas G, Weber M, Mayerhoefer ME.
    Clin Nucl Med; 2017 Sep; 42(9):669-674. PubMed ID: 28682844
    [Abstract] [Full Text] [Related]

  • 14. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I.
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [Abstract] [Full Text] [Related]

  • 15. 68Ga DOTANOC PET/CT in primary neuroendocrine tumor of the breast.
    Mukherjee A, Karunanithi S, Singla S, Bal C, Kumar R.
    Clin Nucl Med; 2014 Apr; 39(4):396-8. PubMed ID: 24566407
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.
    Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, Delbeke D, Walker RC.
    J Nucl Med; 2016 Jun; 57(6):872-8. PubMed ID: 26769864
    [Abstract] [Full Text] [Related]

  • 20. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review.
    Evangelista L, Ravelli I, Bignotto A, Cecchin D, Zucchetta P.
    Clin Imaging; 2020 Nov; 67():113-116. PubMed ID: 32559681
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.